描述

The multi-drug resistance (MDR) antibiotics market in China in terms of revenue is set to grow by US$ 3 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 9.7% 在预测期内, 据数据和分析公司 StrategyHelix 称.

该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for multi-drug resistance (MDR) antibiotics. The China multi-drug resistance (MDR) antibiotics market is segmented on the basis of type. 按类型, it is categorized into daptomycin, linezolid, teicoplanin, and tigecycline.

The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. 有限公司, Jiangsu Hansoh Pharmaceutical Group Co. 有限公司, North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. 有限公司, Zhejiang Medicine Co. 有限公司.

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the multi-drug resistance (MDR) antibiotics market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

类型: daptomycin, linezolid, teicoplanin, and tigecycline
考虑年数: 本报告涵盖期间 2017 到 2027

利益相关者的主要好处

Get a comprehensive picture of the China multi-drug resistance (MDR) antibiotics market
精准定位增长领域和投资趋势
Understand what the future of the multi-drug resistance (MDR) antibiotics market in China looks like
确定竞争格局和机会之窗

目录

1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Multi-Drug Resistance (MDR) Antibiotics Market by Type
4.1 Daptomycin
4.2 Linezolid
4.3 Teicoplanin
4.4 Tigecycline
5. 公司简介
5.1 Chia Tai Tianqing Pharmaceutical Group Co., 有限公司.
5.2 Jiangsu Hansoh Pharmaceutical Group Co., 有限公司.
5.3 North China Pharmaceutical Company Ltd.
5.4 Pfizer, 公司.
5.5 Zhejiang Hisun Pharmaceutical Co., 有限公司.
5.6 Zhejiang Medicine Co., 有限公司.
6. 附录
6.1 关于StrategyHelix
6.2 免责声明